Breaking News

Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis U.S. Small Business Administration Applications are Required before FEMA Individual Assistance can be Provided Apply for Assistance Even If You Are Unsure Department of Labor cites Dollar Tree again for endangering workers, continuing company’s lengthy history of workplace safety violations False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents Administrator Samantha Power Meets with Foreign Minister of Sri Lanka Ali Sabry | Readout FIS Challenges Nearly 200 Startups to Pitch their Boldest Ideas in First APAC Fintech Competition

GSK announces core EPS of 112.2p and dividend of 78p

  • Core EPS of 112.2p (+4% CER) and dividend of 78p (+5%)
  • £5.2 billion of cash returned to shareholders through 5% increase in 2013 dividend to 78p, (Q4 23p) and repurchase of £1.5 billion of shares
  • Exceptional year for R&D delivery with approvals for six major products and five additional regulatory filings completed
  • New product launches strengthen businesses in Respiratory, Vaccines, HIV and Oncology

Pipeline opportunity remains substantial with Phase III data for six potential new drugs and vaccines and around ten NME Phase III starts across 2014 and 2015.

View full Q4 2013 results (PDF)

More details with CEO and CFO interview available in the quarterly results section of this website.

Source link